MCA logo

PUBLIC PORTAL

MEDICALLY REVIEWED

Immune Checkpoint Inhibitors in Oncology: Pembrolizumab (Keytruda)

pembrolizumab keytruda immunology cancer oncology drug medication

Tumours harness several strategies to avoid elimination by the immune system and exploiting the programmed cell death protein (PD1) is a key component. Studies have shown that the expression of PD1 by tumour-infiltrating lymphocytes is . . .

Sign Up or Log In as a healthcare professional to read the full article.

Share via

Also worth reading

People also read: